@article{36bbce31ef424e98bd5ff57bde52cff5,
title = "Budesonide and risk of pneumonia - Authors' reply",
author = "Sin, {Don D.} and Peter Calverley and Finn Radner and Rennard, {Stephen I.} and Donald Tashkin",
note = "Funding Information: DDS and DT have received honoraria for speaking engagements and research funding from AstraZeneca and GlaxoSmithKline, makers of inhaled corticosteroids. PC has received honoraria and research funding from AstraZeneca, GlaxoSmithKline, Nycomed, and Boehringer Ingelheim. FR is an employee of AstraZeneca. SIR has received honoraria for speaking, consulting, or research funding from AstraZeneca, GlaxoSmithKline, Schering Plough, Aradigm, Boehringer Ingelheim, Novartis, Pfizer, Mpex, Pulmatrix, Theradvance, Uptake Medical, Wyeth, Nycomed, Almirall, Forest, Dey, Biomark, and Centocor since 2008. Funding Information: Andrea Kramer and Rijk Gans raise several important points that require clarification. As stated in the paper, financial support for the analysis was obtained from the Michael Smith Foundation for Health Research (MSFHR)—a governmental funding agency, and not from AstraZeneca. All of the authors, including three AstraZeneca employees, had an integral role in the analysis, and their contributions (as well as any conflicts of interest) are clearly stated. MSFHR, which provided the funding, had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All of the trials included in our analysis were found in Medline and Embase; Planet did not yield any additional studies. The search terms and strategies are provided in the web supplement of the paper. ",
year = "2009",
doi = "10.1016/S0140-6736(09)62147-4",
language = "English (US)",
volume = "374",
pages = "2051--2052",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier B.V.",
number = "9707",
}